China SXT Pharmaceuticals Statistics
Total Valuation
SXTC has a market cap or net worth of $1.56 million. The enterprise value is -$6.81 million.
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
SXTC has 3.48 million shares outstanding. The number of shares has increased by 224.91% in one year.
| Current Share Class | 3.48M |
| Shares Outstanding | 3.48M |
| Shares Change (YoY) | +224.91% |
| Shares Change (QoQ) | +145.95% |
| Owned by Insiders (%) | 11.80% |
| Owned by Institutions (%) | 1.35% |
| Float | 3.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.20 |
| Forward PS | n/a |
| PB Ratio | 0.07 |
| P/TBV Ratio | 0.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.60, with a Debt / Equity ratio of 0.27.
| Current Ratio | 1.60 |
| Quick Ratio | 1.51 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.78 |
Financial Efficiency
Return on equity (ROE) is -21.65% and return on invested capital (ROIC) is -6.34%.
| Return on Equity (ROE) | -21.65% |
| Return on Assets (ROA) | -4.96% |
| Return on Capital (ROIC) | -6.34% |
| Revenue Per Employee | $25,713 |
| Profits Per Employee | -$41,314 |
| Employee Count | 75 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 1.98 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 1.12 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.46 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 57.16 |
| Average Volume (20 Days) | 2,221,644 |
Short Selling Information
| Short Interest | 261,990 |
| Short Previous Month | 72,132 |
| Short % of Shares Out | 1.84% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.52 |
Income Statement
In the last 12 months, SXTC had revenue of $1.93 million and -$3.10 million in losses. Loss per share was -$3.57.
| Revenue | 1.93M |
| Gross Profit | 553,971 |
| Operating Income | -2.09M |
| Pretax Income | -14.14M |
| Net Income | -3.10M |
| EBITDA | -1.89M |
| EBIT | -2.09M |
| Loss Per Share | -$3.57 |
Full Income StatementBalance Sheet
The company has $12.07 million in cash and $3.70 million in debt, giving a net cash position of $8.38 million or $2.41 per share.
| Cash & Cash Equivalents | 12.07M |
| Total Debt | 3.70M |
| Net Cash | 8.38M |
| Net Cash Per Share | $2.41 |
| Equity (Book Value) | 13.93M |
| Book Value Per Share | 6.28 |
| Working Capital | 5.33M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.93 million and capital expenditures -$7,063, giving a free cash flow of -$1.94 million.
| Operating Cash Flow | -1.93M |
| Capital Expenditures | -7,063 |
| Free Cash Flow | -1.94M |
| FCF Per Share | -$0.56 |
Full Cash Flow StatementMargins
Gross margin is 28.73%, with operating and profit margins of -108.49% and -160.67%.
| Gross Margin | 28.73% |
| Operating Margin | -108.49% |
| Pretax Margin | -160.67% |
| Profit Margin | -160.67% |
| EBITDA Margin | -97.95% |
| EBIT Margin | -108.49% |
| FCF Margin | n/a |